It’s been a crucial week for Antares Pharma, Inc. (NASDAQ:ATRS); here’s what analysts have to say.

Investors sentiment increased to 1.74 in 2018 Q4. Its up 0.53, from 1.21 in 2018Q3. It is positive, as 6 investors sold Antares Pharma, Inc. shares while 25 reduced holdings. 24 funds opened positions while 30 raised stakes. 61.54 million shares or 8.31% more from 56.81 million shares in 2018Q3 were reported.
Proshare Advsrs Limited Liability Company holds 15,209 shares or 0% of its portfolio. Susquehanna Grp Ltd Liability Partnership stated it has 148,358 shares. Sectoral Asset Mgmt accumulated 47,280 shares. Jpmorgan Chase And Com owns 36,877 shares for 0% of their portfolio. Moreover, Broadfin Cap Limited Company has 1.23% invested in Antares Pharma, Inc. (NASDAQ:ATRS) for 3.44 million shares. New York State Common Retirement Fund, New York-based fund reported 112,200 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 11,255 shares or 0% of all its holdings. Geode Cap Management Limited Com invested in 0% or 1.61 million shares. Voya Inv Mgmt Limited Liability stated it has 62,618 shares or 0% of all its holdings. Essex Investment Mgmt Co Ltd Liability Co owns 506,300 shares. State Board Of Administration Of Florida Retirement reported 59,413 shares. Avenir owns 290,097 shares for 0.1% of their portfolio. Tiaa Cref Investment Mgmt Ltd Company has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Grp One Trading L P holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 35,046 shares. Lpl Ltd Liability Co reported 13,800 shares.

Antares Pharma, Inc. (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 6 analyst reports since February 22, 2019 according to SRatingsIntel. H.C. Wainwright maintained Antares Pharma, Inc. (NASDAQ:ATRS) on Monday, March 11 with “Buy” rating. Cowen & Co initiated the shares of ATRS in report on Monday, February 25 with “Buy” rating. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) has “Buy” rating given on Friday, February 22 by Jefferies. The rating was maintained by Raymond James with “Strong Buy” on Monday, March 4. Below is a list of Antares Pharma, Inc. (NASDAQ:ATRS) latest ratings and price target changes.

11/05/2019 Broker: BidaskScore Rating: Hold Upgrade
31/03/2019 Broker: BidaskScore Rating: Sell Downgrade
11/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $4.5 Maintain
04/03/2019 Broker: Raymond James Old Rating: Strong Buy New Rating: Strong Buy Old Target: $5.25 New Target: $5.65 Maintain
25/02/2019 Broker: Cowen & Co Rating: Buy New Target: $7 Initiate
22/02/2019 Broker: Jefferies Rating: Buy New Target: $19 Maintain

The stock decreased 1.40% or $0.04 during the last trading session, reaching $2.81. About 686,934 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 74.65% since May 17, 2018 and is uptrending. It has outperformed by 70.28% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $456.96 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More notable recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Globenewswire.com which released: “Antares Pharma Appoints Dr. Karen Smith to Board of Directors and Announces Retirement of Dr. Jacques Gonella – GlobeNewswire” on March 04, 2019, also Globenewswire.com with their article: “Antares Pharma to Report First Quarter 2019 Financial and Operating Results – GlobeNewswire” published on April 18, 2019, Finance.Yahoo.com published: “Investors Who Bought Antares Pharma (NASDAQ:ATRS) Shares Three Years Ago Are Now Up 265% – Yahoo Finance” on May 09, 2019. More interesting news about Antares Pharma, Inc. (NASDAQ:ATRS) were released by: Globenewswire.com and their article: “Antares Pharma to Present at the Raymond James & Associates 40th Annual Institutional Investors Conference – GlobeNewswire” published on February 27, 2019 as well as Seekingalpha.com‘s news article titled: “Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q1 2019 Results – Earnings Call Transcript – Seeking Alpha” with publication date: May 02, 2019.

Antares Pharma, Inc. (NASDAQ:ATRS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.